Summary - CRSP - NASDAQ - Weiss Ratings

D

CRISPR Therapeutics AG CRSP

$56.16 $0.601.08%

Recommendation

Prev Close

Volume

Avg Vol (90D)

Market Cap

Dividend & Yield

--

52-Week Range

$37.55 - $91.10

P/E (TTM)

--

EPS (TTM)

My Lists My Alerts

Report

Rating

Reward

Risk

Rating Factors

Growth Index

Efficiency Index

Solvency Index

Total Return Index

Volatility Index

Dividend Index

--

Headlines

Crispr Therapeutics call volume above normal and directionally bullish

4/18/2024 - The Fly

Samarth Kulkarni Sells 19,582 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

4/18/2024 - Zolmax

Crispr Therapeutics price target raised by $1 at Citi, here's why

4/18/2024 - The Fly

DecisionPoint Financial LLC Increases Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

4/17/2024 - Ticker Report

CRISPR Therapeutics's Options Frenzy: What You Need to Know

4/17/2024 - Benzinga

Slow Capital Inc. Purchases 408 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

4/17/2024 - Ticker Report

Bullish Trendline Has Never Failed Crispr Therapeutics Stock

4/17/2024 - Schaeffers Research: News & Analysis

Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?

4/17/2024 - Zacks Investment Research

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

4/16/2024 - Zacks Investment Research

bluebird (BLUE) Underperforms Industry YTD Amid Challenges

4/16/2024 - Zacks Investment Research

First Week of CRSP May 31st Options Trading

4/16/2024 - Stock Options Channel

Bay Colony Advisory Group Inc d b a Bay Colony Advisors Lowers Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

4/16/2024 - Ticker Report

Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

4/16/2024 - Simply Wall St

Carnegie Capital Asset Management LLC Sells 15,180 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

4/15/2024 - Ticker Report

Perigon Wealth Management LLC Boosts Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

4/14/2024 - Zolmax

Sequoia Financial Advisors LLC Increases Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

4/14/2024 - Zolmax

3 Magnificent Stocks That Could Double or More by 2030

4/13/2024 - Fool.com Headlines

Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex

4/12/2024 - Zacks Investment Research

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Harbor Investment Advisory LLC

4/12/2024 - Ticker Report

Krilogy Financial LLC Buys Shares of 15,694 CRISPR Therapeutics AG (NASDAQ:CRSP)

4/11/2024 - Ticker Report

Baillie Gifford & Co. Reduces Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

4/11/2024 - Ticker Report

Charles River (CRL) Forges Collaboration With Ship of Theseus

4/11/2024 - Zacks Investment Research

Crispr Therapeutics AG: A Buy Rating Backed by Innovative Gene-Editing Prospects and Strategic Growth

4/11/2024 - TipRanks Financial Blog

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference - (Transcript)

4/10/2024 - SeekingAlpha

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference - (Transcript)

4/10/2024 - Seeking Alpha: Transcripts

Income Statement

Total Revenue (TTM)

EBITDA (TTM)

EBIT (TTM)

Net Income (TTM)

Balance Sheet

Total Assets (Q)

Total Debt (Q)

Total Liabilities (Q)

Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)

Cash from Investing (TTM)

Cash from Financing (TTM)

Net Change in Cash (TTM)

Filings

Filing Date

Wednesday, February 21, 2024

Period Date

Sunday, December 31, 2023

Next Filing

Week of May 6 and 10 (est)

Price History

Loading...

Beta

7-Day Total Return

30-Day Total Return

60-Day Total Return

90-Day Total Return

Year to Date Total Return

1-Year Total Return

2-Year Total Return

3-Year Total Return

5-Year Total Return

52-week Low

Oct 23, 2023 - $37.55

52-week High

Feb 22, 2024 - $91.10

Valuation

Market Cap

$5.15B - Mid Cap

Enterprise Value

Price/Sales (TTM)

Price/Book (Q)

Dividends and Shares

Shares Outstanding

Dividend Per Share (Most Recent)

--

Dividend Per Share (TTM)

--

Corporate Info

Website

www.crisprtx.com

Phone Number

41 41 561 32 77

Address

Baarerstrasse 14
Zug, 6300

Country

Year Founded

Business Description

Sector

Industry

Pharmaceuticals, Biotechnology and Life Sciences

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats... more